Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy
Cancer, 04/25/2012
Clinical Article
Defina M et al. – This study assessed for the first time the persistence of CD34+Ph+ cells during nilotinib first–line treatment. Preliminary results showed that in patients in CCyR, even after short–term nilotinib therapy, residual leukemic progenitors are very rarely detected compared with imatinib–treated CCyR patients.
